Quick Take
Castle Biosciences (CSTL) went public in July 2019, pricing its IPO shares at $16.00.
The firm is commercializing cancer diagnostic and prognostic testing products and services.
CSTL has grown revenue and gross profit at an impressive trajectory and the firm expects to launch its next predictive skin cancer test by the end of 2020.
My bias on the stock is Bullish.
Company
Friendswood, Texas-based Castle Bio was founded in 2007 to bring ‘actionable genomic information to the diagnosis and treatment of skin and uveal cancers.’
Management is headed by founder and